Evidence map›Paper›PMID 41775875›Full record

ArticleNPJ cardiovascular health2025

Polygenic risk scores improve CAD risk prediction in individuals at borderline and intermediate clinical risk.

Dariusz Ratman, Placede Tshiaba, Michael Levin, Jiayi Sun, Tate Tunstall, Robert Maier, Premal Shah, Matthew Rabinowitz, Daniel J Rader, Akash Kumar and 1 more

Abstract read
In one paragraph

Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dariusz Ratman *MyOme Inc, Menlo Park, CA, USA.
Placede Tshiaba *MyOme Inc, Menlo Park, CA, USA.
Michael LevinDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jiayi SunMyOme Inc, Menlo Park, CA, USA.
Tate TunstallMyOme Inc, Menlo Park, CA, USA.
Robert MaierMyOme Inc, Menlo Park, CA, USA.
Premal ShahMyOme Inc, Menlo Park, CA, USA.
Matthew RabinowitzMyOme Inc, Menlo Park, CA, USA.
Daniel J RaderDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Akash KumarMyOme Inc, Menlo Park, CA, USA.
Kate ImMyOme Inc, Menlo Park, CA, USA. kate@myome.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polygenic risk scores (PRSs) can improve clinical risk tools for coronary artery disease (CAD). This study assessed a risk model integrating PRS across populations, focusing on individuals with borderline/intermediate clinical risk. We developed ancestry-specific ensemble models combining multi-ancestry PRSs for CAD and type 2 diabetes. The cross-ancestry PRS (caPRS) was integrated with the Pooled Cohort Equations (PCE) to derive the cross-ancestry Integrated Risk Score (caIRS), estimating 10-year CAD risk. The caIRS outperformed the PCE across four cohorts, including UK Biobank and Penn Medicine Biobank, with significant improvements for Hispanic and South Asian individuals. For those at borderline/intermediate PCE risk (5-20%), the caIRS reclassified between 7.0% and 10.7% into the high-risk group, which had higher CAD incidence and hazard ratios ranging from 3.20 to 3.84. The CAD caIRS, combining genetic and clinical factors, enhances high-risk CAD identification across diverse populations, potentially improving treatment guidance.

Identifiers

PMID41775875
PMCPMC12912298

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.